A clinical-stage medtech company in Cantù, near Como

Dialybrid builds on two decades of advanced materials research at Bioengineering Laboratories to develop vascular grafts for hemodialysis and other vascular applications.

Surgical team preparing a vascular access procedure

How we got here

  1. 2001Francesco Greco founds Bioengineering Laboratories (BEL), where research on nanostructured natural and synthetic polymers leads to Silkothane®.
  2. August 2020Dialybrid is founded through a partnership between LIFTT (Fondazione Compagnia di San Paolo and Politecnico di Torino), BEL and Francesco Greco. Como Venture joins later.
  3. 2023 to 2025Preclinical results presented at the Vascular Access Society congresses in Porto and Padova.
  4. Summer 2026€15 million Series A led by XGEN Venture, with CDP Venture Capital (Fondo Rilancio).
  5. 2026First patient implanted in the first-in-human study in Varese.

Leadership

Portrait of Francesco Greco

Francesco Greco

Founder, Chairman and Chief Executive Officer

A Politecnico di Milano graduate and pioneer of biomedical engineering in Italy. He founded Medical Technology (1989) and Bioengineering Laboratories (2001), is co-inventor of around 20 patent applications and co-inventor of the patent behind Silkothane®.

Portrait of Stefania A. Riboldi

Stefania A. Riboldi

Chief Technology Officer

Biomedical engineer with a Ph.D. in Tissue Engineering from Politecnico di Milano and research at ETH Zürich. R&D Manager at BEL from 2008 to 2020, focused on polyurethanes and electrospinning.

Talk to the Dialybrid team.

info@dialybrid.com

Dialybrid S.r.l.
Via Antonio Vivaldi 32/A
22063 Cantù (CO), Italy
+39 031 7377739